middl
east
respiratori
syndrom
corona
viru
merscov
novel
human
betacoronaviru
first
isol
follow
fatal
patient
sever
acut
respiratori
infect
saudi
arabia
genom
sequenc
public
releas
isol
enabl
develop
sever
realtim
revers
transcriptas
polymeras
chain
reaction
rrtpcr
base
assay
facilit
laboratori
detect
confirm
merscov
rna
clinic
specimen
screen
assay
primarili
target
genom
region
upstream
envelop
gene
upe
confirmatori
assay
target
viral
open
read
frame
corman
et
al
b
recent
altern
genom
target
includ
nucleocapsid
n
lu
et
al
rnadepend
rna
polymeras
gene
corman
et
al
follow
deploy
molecular
assay
report
merscov
case
continu
rise
region
global
accord
statist
august
total
laboratori
confirm
merscov
case
includ
relat
death
report
countri
rapid
reliabl
detect
merscov
therefor
essenti
control
spread
emerg
threat
event
merscov
outbreak
world
health
organ
author
emerg
use
rrtpcr
assay
merscov
detect
merscov
rtpcr
assay
corman
et
al
commerci
avail
assay
produc
altona
diagnost
hamburg
germani
ii
cdc
novel
coronaviru
realtim
rtpcr
assay
lu
et
al
distribut
free
charg
qualifi
laboratori
center
diseas
control
prevent
atlanta
ga
usa
initi
stage
merscov
spread
assay
enabl
rapid
diagnosi
support
public
health
respons
merscov
howev
current
avail
commerci
assay
evalu
clinic
sensit
kit
limit
viru
spike
mock
sampl
small
number
clinic
specimen
merscov
infect
case
due
recent
increas
commerci
avail
merscov
rrtpcr
kit
n
pa
et
al
need
evalu
assay
perform
differ
specimen
type
better
understand
diagnost
effect
lower
respiratori
tract
lrt
specimen
known
contain
high
viral
load
howev
upper
respiratori
tract
urt
specimen
diagnost
microbiolog
infecti
diseas
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
g
c
r
b
nasopharyngealoropharyng
npop
swab
remain
easiest
common
specimen
type
collect
patient
experienc
respiratori
distress
articl
describ
perform
evalu
commonli
use
commerci
merscov
rrtpcr
assay
modifi
protocol
larg
panel
urt
specimen
collect
period
surround
outbreak
episod
riyadh
saudi
arabia
late
winter
earli
spring
period
king
khalid
univers
hospit
kkuh
riyadh
saudi
arabia
observ
outbreak
merscov
infect
specimen
screen
rtpcr
use
merscov
rrtpcr
assay
laboratoryconfirm
sampl
also
subject
deep
sequenc
phylogenet
analysi
previous
describ
somili
et
al
studi
archiv
combin
npop
swab
viral
transport
medium
vtm
copan
brescia
itali
patient
present
probabl
suspect
diagnosi
merscov
attend
kkuh
period
surround
outbreak
januari
april
obtain
molecular
diagnost
unit
kkuh
includ
archiv
npop
swab
vtm
sequenceconfirm
merscovposit
case
randomli
select
merscovneg
npop
swab
aliquot
vtm
origin
frozen
npop
tube
specimen
prepar
tube
specimen
delink
patient
detail
reissu
uniqu
studi
identifi
reextract
concurr
subject
merscov
rrtpcr
describ
research
perform
test
blind
origin
merscov
screen
outcom
specimen
merscov
rrtpcr
assay
use
gold
standard
result
merscov
assay
tabl
repres
result
reextract
specimen
compar
analysi
addit
divers
clinic
profici
test
specimen
previous
posit
respiratori
virus
use
detect
assay
seegen
seoul
korea
section
also
includ
studi
evalu
assay
crossreact
studi
approv
perform
accord
guidelin
kkuh
colleg
medicin
institut
review
board
committe
project
number
total
nucleic
acid
extract
vtm
aliquot
perform
magna
pure
compact
system
roch
appli
scienc
bavaria
germani
use
nucleic
acid
isol
kit
default
instrument
set
extract
perform
specimen
final
elut
volum
duplic
extract
perform
specimen
final
elut
pool
one
extract
concurr
use
tabl
summar
specif
merscov
rrtpcr
assay
use
studi
amplif
perform
accord
manufactur
instruct
assay
suppli
complet
kit
inclus
master
mix
reagent
intern
control
except
tib
lightmix
kit
tib
molbiol
berlin
germani
use
multiplex
rna
viru
master
mix
roch
appli
scienc
assay
assay
signatur
except
seegen
discuss
target
upe
genom
region
merscov
screen
gene
confirmatori
investig
posit
upe
amplif
confirm
merscov
infect
purpos
studi
specimen
analyz
screen
confirmatori
assay
addit
intern
control
spike
pcr
mixtur
accord
manufactur
instruct
modif
assay
also
evalu
unmodifi
assay
assay
reaction
composit
follow
onestep
qrtpcr
master
mix
primer
design
ad
primerprob
mix
intern
extract
control
primerprob
mix
extract
sampl
rna
control
control
materi
use
reaction
volum
adjust
water
amplif
perform
system
use
thermocycl
condit
specifi
modifi
protocol
assay
multiplex
rna
viru
master
mix
use
place
master
mix
follow
reaction
volum
set
contain
rt
qpcr
reaction
mix
rt
enzym
primerprob
mix
nucleasefre
water
extract
sampl
rna
control
materi
amplif
thermocycl
describ
time
perform
studi
seegen
qualit
assay
commerci
avail
still
valid
stage
detail
target
disclos
howev
prepar
manuscript
seegen
sinc
releas
new
ce
vitro
diagnost
ivd
mark
semiquantit
merscov
assay
replac
first
gener
assay
base
detect
popular
upe
target
enabl
screen
confirm
merscov
infect
describ
addit
tib
also
releas
new
ceivd
mark
assay
detect
upe
n
gene
incorpor
intern
control
ad
extract
stage
monitor
entir
process
nucleic
acid
extract
amplif
howev
origin
assay
describ
still
commerci
avail
use
merscov
diagnost
assay
crossreact
evalu
use
profici
test
specimen
obtain
colleg
american
pathologist
clinic
specimen
previous
identifi
posit
respiratori
virus
merscov
ii
detect
assay
seegen
use
confirm
presenc
respiratori
virus
includ
adenoviru
influenza
b
virus
parainfluenza
virus
human
rhinoviru
respiratori
syncyti
virus
b
human
bocaviru
metapneumoviru
coronaviru
coronaviru
coronaviru
enteroviru
briefli
total
nucleic
acid
extract
describ
section
except
extract
intern
control
ad
specimen
revers
transcript
stage
complementari
dna
cdna
synthes
use
cdna
synthesi
premix
kit
seegen
two
microlit
random
hexam
extract
rna
ad
prealiquot
tube
contain
cdna
synthesi
master
mix
amplifi
accord
manufactur
instruct
complet
realtim
respiratori
viru
detect
reaction
set
use
toma
tomb
set
master
mix
togeth
enabl
detect
respiratori
virus
intern
control
duplic
reaction
volum
set
contain
cdna
primer
toma
tomb
master
mix
water
amplif
detect
perform
system
biorad
follow
condit
activ
minut
denatur
minut
follow
cycl
second
minut
second
catcher
melt
temperatur
analysi
cmta
perform
cool
mixtur
maintain
mixtur
second
heat
mixtur
cmta
perform
time
amplif
cycl
number
fluoresc
continu
measur
temperatur
increas
stage
final
meltpeak
analysi
perform
seegen
viewer
softwar
seegen
evalu
diagnost
perform
commerci
merscov
rrtpcr
assay
show
tib
lightmix
assay
best
clinic
sensit
follow
seegen
assay
tabl
compar
cycl
threshold
c
valu
detail
tabl
except
seegen
assay
provid
qualit
detect
intern
control
applic
valid
minim
c
variat
tib
lightmix
assay
display
sensit
clinic
specimen
pool
two
specimen
yield
posit
upe
gene
amplif
without
amplif
confirmatori
target
ii
posit
gene
amplif
without
amplif
upe
target
tabl
result
neg
merscov
classif
seegen
assay
display
modest
sensit
howev
origin
assay
assay
lack
sensit
particularli
specimen
display
low
viral
load
high
c
valu
compar
assay
compar
modif
protocol
assay
improv
merscov
rna
detect
randomli
select
merscovneg
respiratori
specimen
collect
period
assay
display
neg
rrtpcr
result
addit
crossreact
evalu
use
specimen
posit
respiratori
virus
specif
seegen
assay
tabl
tib
lightmix
assay
produc
limit
crossreact
influenza
bposit
clinic
specimen
confirm
ii
assay
blindtest
protocol
extract
rna
sampl
use
studi
also
retest
merscov
rrtpcr
assay
gold
standard
c
valu
also
display
tabl
known
posit
specimen
yield
posit
result
indic
archiv
month
compromis
specimen
integr
assay
case
yield
lower
c
valu
assay
assay
also
display
crossreact
respiratori
virus
present
rtpcr
detect
merscov
rna
remain
reliabl
method
laboratori
confirm
infect
howev
actual
gold
standard
yet
classifi
assay
reli
gene
signatur
screen
confirm
merscov
rna
compar
analysi
merscov
rrtpcr
assay
evalu
clinic
sensit
present
c
valu
enabl
robust
comparison
diagnost
assay
perform
npop
specimen
test
condit
although
c
valu
differ
assay
affect
variou
assay
compon
platform
use
analys
urt
specimen
show
tib
lightmix
assay
sensit
follow
seegen
protocol
discord
result
assay
seen
specimen
contain
low
viru
concentr
high
c
valu
reflect
differ
limit
detect
lod
evalu
lod
critic
prevent
underdiagnos
merscov
infect
consider
select
commerci
assay
routin
diagnost
purpos
european
viru
archiv
produc
quantit
standard
upe
howev
unabl
obtain
standard
investig
nevertheless
tib
lightmix
protocol
assay
produc
singl
geneposit
indetermin
result
clinic
diagnost
set
would
requir
confirm
screen
secondari
specimen
ideal
lrt
higher
viral
load
expect
overal
interpret
merscov
neg
addit
seegen
assay
also
produc
sever
neg
classif
sequenceconfirm
specimen
indetermin
neg
result
observ
assay
although
tib
lightmix
assay
sensit
assay
secondari
display
limit
crossreact
influenza
b
need
investig
howev
kingdom
saudi
arabia
polici
perform
parallel
screen
merscov
influenza
b
suspect
merscov
case
reason
would
easi
identifi
potenti
crossreact
assay
nevertheless
tib
assay
effici
assay
yield
amplif
result
within
minut
would
highli
advantag
outbreak
situat
turnaround
time
critic
reduc
sensit
assay
thought
result
suboptim
perform
lyophil
rt
enzym
primer
detect
common
merscov
target
upe
whitak
et
al
propos
assay
perform
may
improv
replac
lyophil
rtpcr
nonlyophil
counterpart
agre
conclus
use
multiplex
rna
viru
master
mix
primer
assay
significantli
improv
assay
sensit
accord
recent
publish
studi
evalu
first
merscov
extern
qualiti
assess
eqa
panel
report
commerci
rrtpcr
assay
use
particip
routin
diagnost
merscov
assay
includ
studi
among
popular
pa
et
al
eqa
panel
sampl
includ
merscovposit
sampl
gave
merscov
rrtpcr
assay
sensit
score
find
support
superior
sensit
merscov
rrtpcr
assay
reduc
sensit
assay
even
urt
specimen
reanalysi
known
posit
specimen
merscov
rrtpcr
assay
show
consist
lower
c
valu
specimen
enabl
reliabl
merscov
detect
assay
approach
diagnost
cutoff
howev
could
possibl
attribut
larger
nucleic
acid
input
volum
amplif
reaction
volum
rel
assay
studi
kim
et
al
evalu
analyt
clinic
sensit
commerci
merscov
rrtpcr
assay
use
korea
lightmix
assay
common
studi
although
util
differ
pcr
platform
lightcycl
versu
lightcycl
assay
use
studi
highlight
divers
merscov
test
avail
korea
saudi
arabia
kim
et
al
abl
util
updat
version
assay
although
preceivd
approv
detect
upe
intern
control
versu
version
assay
use
studi
incorpor
meltpeak
analysi
nine
lrt
sputum
specimen
use
determin
assay
sensit
lrt
specimen
use
evalu
effect
pcr
inhibit
posit
result
nasopharyng
swab
use
evalu
assay
crossreact
overal
sensit
specif
assay
deem
suffici
diagnost
use
howev
sputum
specimen
shown
particularli
pcr
inhibit
prone
neg
impact
assay
sensit
highlight
import
optim
pretreat
rna
extract
procedur
use
specimen
type
comparison
pcr
inhibit
observ
npop
specimen
use
present
studi
minim
variat
observ
intern
control
c
valu
nevertheless
c
valu
lightmix
assay
report
sputum
specimen
kim
et
al
compar
urt
specimen
limit
studi
evalu
urt
specimen
recommend
preferenti
collect
lrt
specimen
eg
broncheoalveolar
lavag
tracheal
aspir
merscov
molecular
diagnost
contain
higher
viral
load
howev
lrt
specimen
tradit
collect
patient
requir
hospit
nevertheless
possibl
screen
urt
specimen
still
accept
diagnost
valu
demonstr
result
report
investig
diagnost
accuraci
commerci
merscov
rrtpcr
assay
npop
swab
although
ultim
merscov
diagnosi
reli
singl
assay
studi
may
contribut
toward
better
understand
diagnost
perform
current
avail
merscov
rrtpcr
assay
lightmix
assay
describ
still
wide
use
kingdom
saudi
arabia
magna
pure
compact
autom
nucleic
acid
extract
system
studi
support
upe
genom
region
wellchosen
amplif
target
merscov
diagnost
howev
need
develop
rapid
diagnost
assay
shorter
turnaround
time
